Velodyne Lidar’s Groundbreaking Sensors Power Kaarta Mobile Mapping
Velodyne Lidar, Inc. today announced Kaarta has included Velodyne’s smart, powerful lidar technology in Kaarta’s new Stencil 2-32 ground surface mapping solution. Equipped with Velodyne lidar, Stencil 2-32 accurately scans ground level surfaces, mapping items such as curbs, manholes, signs, poles, and other features at a fraction of the cost of traditional mobile mapping systems. The Stencil platform helps enable city planning for infrastructure improvements as well as parking and traffic management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190716005210/en/
Kaarta’s new Stencil 2-32 ground surface mapping solution includes Velodyne’s smart, powerful lidar technology. (Photo: Business Wire)
The 3D data generated by Stencil 2-32 can be utilized for a range of applications including BIM modeling, geospatial data analytics, and cataloging tools. For example, Allvision uses Stencil 2-32 along with data from an autonomous vehicle developer to conduct curb occupancy analysis in Pittsburgh’s Strip District, an area known for high on-street parking demands. Called Allvision Parkview, the solution allows city planners to monitor parking behavior to improve transportation planning and curb management.
“The addition of Stencil 2-32 to Kaarta’s product line further extends the range of mapping applications for mobile lidar scanning,” said Kevin Dowling, Ph.D., CEO, Kaarta. “The low noise, long range, and field of view of Velodyne’s compact lidar sensors allow us to create systems with immense versatility, accuracy, and speed – from capture to answer.”
Stencil integrates 3D mapping and real-time position estimation to create capabilities not possible with fixed-base scanning systems. Stencil 2-32 incorporates the Velodyne HDL-32E lidar sensor, which provides a range of 100 meters and a data rate of 720,000 points per second. Kaarta leverages advanced robotics technology that combines input from multiple sensors – lidar, visual odometry, and inertial measurement unit (IMU) – and processes that data in real time. For some applications, the data can be enhanced with Global Navigation Satellite System (GNSS) positioning and wheel odometry sensors.
“Velodyne lidar and Kaarta’s advanced 3D mapping and localization algorithms are a phenomenal combination, creating a portable system for fast and easy detailed surface mapping,” said Aaron Morris, Founder and CEO, Allvision. “The ability to rapidly gather accurate and up-to-date geospatial information has countless applications.”
Stencil 2-32 is the newest member of Kaarta’s Stencil product line which also includes Stencil 2-16, a versatile low-cost mobile mapping platform that uses the Velodyne Puck™ sensor. Its ease of use, breadth of applications, and streamlined workflow make the system well-suited for infrastructure inspectors, surveyors, engineers, architects, facilities planners, security personnel, and more.
“Kaarta and Allvision demonstrate how to tap the full potential of Velodyne’s rich computer perception data for an innovative solution to inventory, track, and monitor assets for accurate future planning and management,” said Mike Jellen, President and CCO, Velodyne Lidar.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Founded in 1983 and headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. In 2005, Velodyne’s Founder and CEO, David Hall, invented real-time surround view lidar systems, revolutionizing perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Puck™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.
Kaarta is the innovator of real-time mobile 3D reality capture, mapping complex environments with unprecedented speed, fidelity and ease. Kaarta works without external signal infrastructure such as GPS or Wi-Fi. Kaarta’s patent-pending technology, rooted in advanced robotics, accurately transforms the real world into 3D digital twins, streamlining workflow, reducing time, lowering cost, and providing a new level of understanding of spaces for humans and autonomous machines alike. Now the spectrum of stakeholders across architecture, engineering, construction, and property owner/operators, facilities planners and managers, and mobile robotics developers can work from the same truth. Additional information is available at www.kaarta.com.
Landis Communications Inc. for Velodyne Lidar, Inc.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment7.12.2019 19:00:00 CET | Press release
Kite, a Gilead Company (Nasdaq: GILD), today announced new data from the ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. These results included updated overall survival data from the pivotal phase 2 study after three years following a single infusion of Yescarta, as well as an analysis from a separate safety management cohort of patients receiving early steroid intervention for cytokine release syndrome (CRS) and neurologic events. The data were presented today at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, in Orlando from December 7–10, 2019. With a minimum follow-up of three years after a single infusion of Yescarta (median follow-up of 39.1 months), approximately half (n=47/101; 47 percent) of patients with refractory large B-cell lymphoma in ZUMA-1 pivotal phase 2 cohorts were alive, and the median overall survival (OS) was 25.8 months. These updated three-year survival data were presented a
Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma7.12.2019 15:20:00 CET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being evaluated in the treatment of patients with relapsed or refractory multiple myeloma. The study enrolled patients who had received at least three prior lines of therapy or were double refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD); had received a PI, IMiD and an anti-CD38 antibody. The CARTITUDE-1 study results, premiered at the American Society of Hematology (ASH) Annual Meeting, were featured as an oral presentation and highlighted in the official ASH press programme (Abstract #577).1 Results from the Phase 1b portion of the CARTITUDE-1 study showed early and deep responses among patients (n=29) with a median of five prior multiple myeloma
Imbruvica®▼(ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukaemia7.12.2019 15:18:00 CET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced combination data from two studies and a long-term integrated analysis evaluating the use of Imbruvica® (ibrutinib) for the treatment of previously untreated patients with CLL. Results from a 48-month follow-up analysis of the Phase 3 E1912 clinical study reported a statistically significant difference in PFS and OS for ibrutinib plus rituximab compared to a standard chemoimmunotherapy regimen of FCR.1 Further, the latest integrated analysis from the Phase 3 RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115/1116) studies investigating the use of single-agent ibrutinib in CLL, reported at up to six years of follow-up, PFS, OS and response rates improved when ibrutinib was used in earlier lines of therapy.2 During this extended follow-up, ibrutinib was tolerated across all lines of therapy with 19 percent of patients discontinuing due to adverse events.2 In addition, results presented from the Phase 2 CAPTIVATE stu
Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis7.12.2019 14:30:00 CET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019 in Orlando, Florida. TOURMALINE-AL1 is a Phase 3, randomized clinical trial evaluating the effect of NINLAROTM (ixazomib) in combination with dexamethasone in patients with relapsed or refractory systemic light-chain (AL) amyloidosis. The TOURMALINE-AL1 trial did not meet the first of the two primary endpoints of significant improvement in overall hematologic response, as reported in June 2019. Hematologic responses were seen in 53% versus 51% of patients receiving NINLARO plus dexamethasone versus physician’s choice (odds ratio 1.10 [95% CI 0.60-2.01], p=0.762) as assessed by an Adjudication Committee (AC). The second primary endpoint of two-year vital organ deterioration or death was not mature at the time of analysis. Other endpoints stu
Schlumberger Announces Fourth-Quarter and Full-Year 2019 Results Conference Call6.12.2019 18:07:00 CET | Press release
Schlumberger Limited (NYSE:SLB) will hold a conference call on January 17, 2020 to discuss the results for the fourth quarter and full year ending December 31, 2019. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 4013483. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 17, 2020, and can be accessed by dialing +1 (866) 207-1041 within North Amer
BUFF STUDIO Globally Launches My Coloring, a Mobile 3D Pixel Art Coloring Book Game6.12.2019 13:00:00 CET | Press release
BUFF STUDIO announced on December 5 that it launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191206005162/en/ BUFF STUDIO launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. My Coloring is a game that materializes a 3D pixel art coloring book on mobile devices. You can blow your stress away as you paint spaces in the order of numbers on the screen while reading calming messages. Relaxing background music you will listen during gameplay and its fairytale-like design will give you pleasure and happiness. You can download it for free on Google Play and the Apple App Store. (Graphic: Business Wire) Its Android and iOS versions were released at the same time so the users can download it for free on Google Play and the Apple App Store. My Coloring is a game that materializes a 3D pixel art col